PremiumCompany AnnouncementsInhibrx Biosciences Shares Latest Corporate Presentation Update
5M ago
Inhibrx files to sell 2.45M shares of common stock for holders
Premium
The Fly
Inhibrx files to sell 2.45M shares of common stock for holders
5M ago
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
5M ago
Inhibrx downgraded to Hold from Buy at Jefferies
PremiumThe FlyInhibrx downgraded to Hold from Buy at Jefferies
8M ago
Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)
Premium
The Fly
Inhibrx reports Q4 EPS ($1.73), consensus ($1.04)
8M ago
Inhibrx Announces Execution of Merger Agreement
Premium
Market News
Inhibrx Announces Execution of Merger Agreement
10M ago
Inhibrx downgraded to Market Perform from Outperform at JMP Securities
PremiumThe FlyInhibrx downgraded to Market Perform from Outperform at JMP Securities
10M ago
Inhibrx reports Q3 EPS ($1.10), consensus ($1.01)
Premium
The Fly
Inhibrx reports Q3 EPS ($1.10), consensus ($1.01)
12M ago
Inhibrx reports preliminary Phase 1 efficacy and safety data in Ewing sarcoma
Premium
The Fly
Inhibrx reports preliminary Phase 1 efficacy and safety data in Ewing sarcoma
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100